medigraphic.com

2016, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2016; 17 (2)

The immune system in lymphedema and lymphangitis of the lower limbs

Mahía VM

Language: Spanish
References: 33
Page: 150-160
PDF size: 186.20 Kb.


ABSTRACT

The immune system is the body´s mechanism of resistance to infections. The lymph system plays an important role in the physiological control of the tissue fluid and in the onset of the immune response. We intended to describe the function of the cell components of the immune system in the cancer-unrelated lymphopathies of the lower limbs such as lymphedema and lymphangitis. To this end, Pubmed, Medline, Scielo, Clinical Key, Liliacs, Ebsco and scientific articles published in Cuban medical journals from 2000 to 2015 were reviewed. The recent studies show that the growth of new lymphatic vessels is a distinctive characteristic of the acute and chronic inflammatory reactions of lymphopathies, mediated by increase of the fluid drainage outside the vessel and of inflammatory cells as well as the immune response modulations. It is urgent to continue studying this topic, mainly the behavior of the humoral and cell immunity in patients suffering from lymphedema or lymphangitis, since no research papers dealing with the possible relation between both aspects were found. It is suggested that the T-cell subpopulations are a key component of the chronic and sub-acute inflammatory response in lymphopaties. Hence, understanding of the regulating function of the lymph fluid in the inflammatory response may represent an important step in the development of therapies that might block the onset or progression of the anomalous consequences of lymphatic injures.


REFERENCES

  1. Abbas AK, Lichtman AH, Pillai S. Inmunología celular y molecular. 6ta ed. EE. UU.: ElsevierSaunder; 2011. Disponible en: http://www.el12cirujano.blogspot.com

  2. Liao S, von der Weid PY. Lymphatic system: An active pathway for immune protection. Semin Cell ÇDev Biol. 2015;38:83.9.doi: 10.1016/j.semcdb.2014.11.012

  3. Rodríguez Villalonga LE. El dilema del linfedema. Rev Cubana Angiol Cir Vasc. 2011 [citado 3 Jul 2012];12(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol12_01_11/ang11111.htm

  4. Rodríguez Villalonga LE, Seuc Jo AH, Lauzán Díaz E, García Lazo G, Rodríguez Álvarez M, Macías Sabuqué M. Linfedemas en el municipio Cerro. Rev Cubana Angiol Cir Vasc. 2012 [citado 30 Sept 2012];13(2). Disponible en: http://bvs.sld.cu/revistas/ang/vol13_2_12/ang03212.htm

  5. Rodríguez Villalonga LE, Victoria García-Viniegras CR, Seuc Jo AH, Pérez Leonard D, Chirino Díaz L, Borrás Migues M. Linfedema y calidad de vida. Rev Cubana Angiol Cir Vasc. 2012 [citado18 May 2013];13(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol13_1_12/ang07112.htm

  6. Fernández de la Vara L. Frecuencia de linfangitis en el cuerpo de guardia. Estudio epidemiológico. Rev Cubana Hig Epidemiol. 1983;21:114-32.

  7. Triana Mantilla ME, Rodríguez Villalonga LE, Morejón Reinoso O, Quíntela Pena AM, Pantaleón Bernal OS, García Miranda AM. Determinación de algunos indicadores bioquímicos en personas con linfedema secundario de miembros inferiores. Rev Cubana Angiol Cir Vasc. 2013 [citado23 Sept 2014];14(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol14_1_13/angio07113.htm

  8. Sorell Gómez L, Fernández de la Vara Sánchez L, Zacca Peña E, Polanco Licea L, Cívico Malet A, González Martín E. Algunos aspectos del pérfil inmunológico de pacientes linfangíticos. Rev Cubana Med. 1987;26(3):306-15.

  9. Castillo MA, Hernández CA, Gravalosa CA, León LA, Charles-Edwards OD. Papel de las vacunas bacterianas en el tratamiento de la linfangitis recidivante. Rev Panam Flebol Linfol. 2000;38:33-40.

  10. Le Guern C. Regulatory T cells tolerance therapy: revisiting the concept. Crit Rev Immunol. 2011;31(3):189–207.

  11. Abbas AK, Benoist C, Bluestone JA, Campbell DJ, Ghosh S, Hori S, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013;14:307–8.

  12. Rouhani SJ, Eccles JD, Tewalt EF, Engelhard VH. Regulation of T-cell tolerance by lymphatic endothelial cells. J Clin Cell Immunol. 2014[citado 15 Abr 2015];5. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286360/pdf/nihms634423.pdf doi:10.4172/21559899.1000242.

  13. Siachoque H, Satisteban N, Iglesias-Gamarra A. Linfocitos T reguladores: sub-poblaciones, mecanismo de acción e importancia en el control de la autoinmunidad. Rev Colomb Reumatol. 2011[citado 4 Sept 2015];18(3).Disponible en: http://www.elsevier.es/es-revista-revista-colombiana-reumatologia-374-linkresolver-linfocitos-t-reguladores-subpoblaciones-mecanismo-90223667

  14. Norrmén C, Tammela T, Petrova TV, Alitalo K. Biological basis of therapeutic lymphangiogenesis. Circulation. 2011;123:1335–51.

  15. Shah B, Rockman CB, Guo Y. Diabetes and Vascular Disease in different arterial territories. Diabetes Care. 2014;37(6):1636-42. doi: 10.2337-dc13-2332

  16. Alitalo Kari. The lymphatic vasculature in disease. Nature Med. 2011;17(11):1371–80.

  17. Cueni< Leah N, Detmar M. The lymphatic system in health and disease. Lymphat Res Biol. 2008;6(3-4):109–22.

  18. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. Cell Biol. 2011;193:607–18. doi: 10.1083/jcb.201012094.

  19. Liao S, Padera TP. Lymphatic function and immune regulation in health and disease. Lymph Res Biol. 2013;11(3):136-43. doi:10.1089/lrb.2013.0012.

  20. Kutkut I, Meens MJ, McKee TA, Bochaton-Piallat ML, Kwak BR. Lymphatic vessels: an emerging actor in atherosclerotic plaque development. Eur J Clin Invest. 2015;45(1):100-8. doi:10.1111/eci.12372.

  21. Koltowska K, Betterman KL, Harvey NL, Hogan BM. Getting out and about: the emergence and morphogenesis of the vertebrate lymphatic vasculature. Development. 2013;140:1857–70. doi:10.1242/dev.089565.

  22. Liao S, Von der Weid PY. Lymphatic system: an active pathway for immune protection. Semin Cell Dev Biol. 2015;38:83-9.

  23. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology and disease. J Cell Biol. 2011;193(4):607-18. doi:10.1083/jcb.201012094.

  24. Zampell JC, Avraham T, Yoder N, Fort N, Yan Y, Weitman ES, Mehrara BJ. Lymphatic function is regulated by a coordinated expression of lymphangiogenic and anti-lymphangiogenic cytokines. Am J Physiol Cell Physiol. 2012;302(2):C392–C404. doi:10.1152/ajpcell.00306.2011

  25. Leah NC, Detmar M. New insights into the molecular control of the lymphatic vascular system and its role in disease. J Invest Dermatol. 2006;126:2167–77. doi:10.1038/sj.jid.5700464

  26. Díaz Hernández OL. Análisis de los factores de riesgo en el linfedema post mastectomía. Rev Cubana Hig Epidemiol. 2000;38(2):127-36.

  27. Robles JI. Linfedema: Una patología olvidada. Psicooncología. 2006;3(1):71-89.

  28. Deng Y, Zhang X, Simons M. Molecular controls of lymphatic VEGFR3 signaling. Arterioscler Thromb Vasc Biol. 2015;35(2):421-9. doi: 10.1161/ATVBAHA.114.304881

  29. Molyneux DH. Tropical lymphedemas. Control and prevention. N Engl J Med. 2012;366:1169-71.

  30. Hartiala P, Saarikko AM. Lymphangiogenesis and lymphangiogenic growth factors. J Reconstr Microsurg. 2016;32(1):10-5. doi:10.1055/s-0035-1544179.

  31. Fernández Montequín JI. Linfangitis y adenitis aguda y crónica. En: Pardo Gómez G, editor. Temas de cirugía. TII. La Habana: Editorial Ciencias Médicas; 2010 [citado 1 Oct 2014]. Disponible en: http://www.tecnetangola.com/downloads/nini/CIRUGIA%20TOMO%20IV_F.pdf

  32. Molski P, Kruczyński J, Molski A, Molski S. Manual lymphatic drainage improves the quality of life in patients with chronic venous disease: a randomized controlled trial. Arch Med Sci. 2013;9(3):452-8. doi:10.5114/aoms.2013.35343

  33. Biancheri D, Depaepe L, Durupt F, Thomas L, Berger F, Balme B. Unusual lymphangitis. Ann Pathol. 2015;35(2):186-8. doi:10.1016/j.annpat.2015.01.002.




2020     |     www.medigraphic.com